Tabelecleucel ( DrugBank: Tabelecleucel )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群2

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04554914
(ClinicalTrials.gov)
July 14, 202114/9/2020A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated DiseasesAn Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated DiseasesStem Cell Transplant Complications;EBV+ Sarcomas;Leiomyosarcoma;Epstein-Barr Virus (EBV)-Associated Diseases;EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD);EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD);EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (CNS PTLD);EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD);Solid Organ Transplant Complications;Lymphoproliferative Disorders;Allogeneic Hematopoietic Cell Transplant;Chronic Active Epstein-Barr Virus (CAEBV);Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH);Lymphohistiocytosis, HemophagocyticBiological: TabelecleucelAtara BiotherapeuticsNULLRecruitingN/AN/AAll228Phase 2United States;Austria;Belgium;France;Italy;Spain;United Kingdom
2NCT02822495
(ClinicalTrials.gov)
October 20, 201630/6/2016Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesExpanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative TherapiesEpstein-Barr Virus (EBV) Infections;Lymphoproliferative Disorders;EBV+ Associated Lymphoma;EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD);Epstein-Barr Viremia;Lymphoma, AIDS-related;Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID);Leiomyosarcoma (LMS);Nasopharyngeal Carcinoma (NPC);Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID);Solid Organ Transplant Complications;Stem Cell Transplant ComplicationsBiological: tabelecleucelAtara BiotherapeuticsNULLTemporarily not availableN/AN/AAllUnited States